In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the latest advancements in Alzheimer’s disease testing and treatment.

Their discussion includes:

• Why there is an increased focus on Alzheimer’s disease in the diagnostics industry.
• The development of groundbreaking blood tests that can detect Alzheimer’s-related biomarkers.
• The importance of accurate testing to avoid false positives.
• The role of laboratory scientists in guiding appropriate test usage.
• The promising new treatment options and the need for informed decision-making in a patient’s healthcare journey.

Further reading:

• Blood biomarkers to detect Alzheimer disease in primary care and secondary care, published July 28, 2024, in JAMA.
• Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p-tau217 immunoassays, published July 19, 2024, in Alzheimer’s & Dementia.
• Innovative Alzheimer’s disease diagnostic tool unveiled, published April 17, 2024, by Mayo Clinic Laboratories.

Podcast episode

Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Podcast episode in video format

Answers from the Lab is a Mayo Clinic Laboratories curated podcast sharing knowledge and advancements regarding the state of testing, laboratory science, and the people who make it all happen behind the scenes. 

Information in this post was accurate at the time of its posting.